Idelalisib in Chronic Lymphocytic Leukemia

2 Views
administrator
administrator
07/08/23

The panelists, William G. Wierda, MD, PhD; Richard R. Furman, MD; and Alessandra Ferrajoli, MD, evaluate the role of idelalisib, a phosphoinositide 3-kinase inhibitor, in the treatment of chronic lymphocytic leukemia.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next